MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
6. Technology Transfer (T2), NonDilutive Funding: Strategy Development
* T2ToolBox
Triple Helix: Reports, Publications & Metrics
Triple Helix: Regional Innovation Clusters (RIC)s
*Bioscience Regional Clusters & HotSpots
*Industry: Massachusetts
Cubist Pharmaceuticals, Inc. (CBST)
Organization & Developments: Cubist
Developments: Cubist
Parents
Organization & Developments: Cubist
Children
2010: 12. Cubist Pharmaceuticals - $118.8M (€87.05M) 2010 R&D
2011: Antibiotic trial to tackle hospital-acquired urinary tract infections (2011)
2011: Cubist Pharmaceuticals' Antibiotic Programs Featured in 18 Abstracts at 21st ECCMID/27th ICC Joint Congress (2011)
2013: Cubist Antibiotic Passes Second Test; FDA Filing Next CBST (2013)
2014: Cubist Wins FDA Approval for New Antibiotic Aimed at Skin Infections
2014: FDA panel votes in favor of approval for Cubist's new MRSA drug
Jumps
Organization: Cubist